These findings indicated that the treatment response could be translated into subsequent survival outcome, and suggested the importance of predictors of treatment efficacy for EGFR TKIs in NSCLC EGFR-mutant patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.